Protagonist Therapeutics stops ulcerative colitis trial of PTG-100
This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. It is based
RiVax has previously been granted orphan drug designation from the US Food and Drug Administration (FDA). The European Commission grants orphan designations for medicines that treat a life-threatening